Home
News
Screeners
Insights
Vivimed Labs
5.
55
+0.10
(+1.83%)
Market Cap
₹46.02 Cr
PE Ratio
-0.25
Industry
Healthcare
Buy
Sell
Company Performance:
1D
+1.83%
1M
-15.27%
6M
-5.93%
1Y
0.00%
5Y
-11.20%
View Company Insights
Latest news about Vivimed Labs
Vivimed Labs seeks 3-month extension to convene FY26 AGM
22 hrs ago
Yesterday
Vivimed Labs CoC approved applying for a 3-month AGM extension. Application filed with Registrar of Companies, Bangalore. Resolution passed via circulation on September 25, 2026. Extension sought for FY26 Annual General Meeting.
Vivimed Labs reports widened net loss in FY26 amid CIRP
Jul 23, 2026
Vivimed Labs confirms no encumbrance on promoter shares in FY26
Jun 18, 2026
Vivimed Labs postpones board meeting for FY26 results
May 31, 2026
Vivimed Labs Schedules Board Meeting on May 28, 2026 to Approve Q4FY26 Financial Results
May 17, 2026
More news about Vivimed Labs
26
Apr 26
Vivimed Labs Limited Enters Corporate Insolvency Resolution Process
Vivimed Labs Limited has entered corporate insolvency resolution process as ordered by National Company Law Tribunal, Bengaluru Bench on 15.04.2026. T Narayana Swamy serves as interim resolution professional, with creditors required to submit claims by 01.05.2026. The process is estimated to conclude by 11.10.2026.
23
Apr 26
Vivimed Labs Limited Insolvency Process: CIRP Commences 15.04.2026
NCLT Bengaluru admitted Vivimed Labs Limited to CIRP on 15.04.2026 over unpaid operational debt of ₹2,78,60,844 owed to Blue Cube Germany Assets. T Narayana Swamy appointed as IRP. Creditors must submit claims by 01.05.2026. The tribunal imposed a moratorium under Section 14 of IBC, prohibiting legal proceedings and asset transfers. Multiple insolvency petitions are pending against the company, indicating broader financial difficulties.
08
Apr 26
Vivimed Labs Submits Q4FY26 SEBI Compliance Certificate to Stock Exchanges
Vivimed Labs Limited has submitted its quarterly compliance certificate under SEBI Regulation 74(5) for Q4FY26 to BSE and NSE, confirming adherence to dematerialization requirements. The certificate, received from RTA Aarthi Consultants Private Limited, covers the period from January 1, 2026 to March 31, 2026, representing routine regulatory compliance for depository operations.
13
Mar 26
Vivimed Labs Reports Widened Q3 FY26 Loss at ₹165.66 Million on Lower Revenue
Vivimed Labs Limited reported significantly worsened financial performance for Q3 FY26 with net loss widening to ₹165.66 million from ₹74.45 million in Q3 FY25, while revenue declined to ₹116.31 million from ₹186.59 million. Nine-month results showed similar deterioration with loss increasing to ₹295.07 million and revenue falling to ₹342.33 million. Consolidated results mirrored standalone trends with Q3 FY26 loss at ₹165.54 million. Auditors expressed qualified conclusions citing unprovided interest charges of ₹164.52 million for the quarter and ongoing forensic audit evaluations.
Vivimed Labs
5.
55
+
0.
10
(+
1.
83
%)
1 Year Returns:
0.00%
Industry Peers
Sun Pharmaceutical
1,852.20
(+
0.
12
%)
Divis Laboratories
9,619.50
(+
0.
18
%)
Torrent Pharmaceuticals
4,988.50
(+
1.
22
%)
Zydus Life Science
1,203.90
(+
2.
00
%)
Cipla
1,399.70
(+
0.
05
%)
Laurus Labs
2,007.00
(-
0.
95
%)
Mankind Pharma
2,474.90
(-
1.
00
%)
Dr Reddys Laboratories
1,201.00
(+
0.
05
%)
Aurobindo Pharma
1,712.00
(-
0.
23
%)
Lupin
2,092.00
(-
0.
41
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO
Cyclical Trend
Events Calendar